• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » AOP Orphan spins off 80% stake in Activartis, outlines business strategy

AOP Orphan spins off 80% stake in Activartis, outlines business strategy

June 19, 2013
CenterWatch Staff

AOP Orphan Pharmaceuticals will spin off its 80% stake in Activartis, a Vienna-based biotech with a platform for immune-based cancer vaccines, to a group of private investors.

The dendritic cell-based technology for individualized tumor therapy developed by Activartis represents a unique therapeutic approach. Clinical development is at an advanced stage for glioblastoma, an incurable disease, and data from a multi-centric, prospective trial are expected soon.

“This spinoff has to be seen in the context of our development and commercialization strategy at AOP Orphan and is a consequence of Elan’s offer to acquire AOP Orphan,” said Rudolf Widmann, chief executive officer of AOP Orphan. “The goal of the Elan scenario would have been to pursue a course of rapid territorial expansion and the addition of several new orphan projects. However, AOP was a minor part of Elan’s management strategy, which included four business proposals, the main one being a royalty-based deal. This strategy was turned down by Elan’s shareholders.”

“AOP Orphan is in a financial position to pursue its research programs as a stand-alone company, and the divestment of Activartis allows it to go for a separate global commercial business case for the cancer vaccine program,” he said. “AOP Orphan will continue its research projects as planned in a timely manner and will launch at least two products within three years in the areas of hematology and cardiology.”

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • MachineLearning-360x240.png

    Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

  • VirtualTraining-360x240.png

    Virtual Training Evolves into More In-Depth Learning, Improved Communications

  • SurveywBlueBackground-360x240.png

    Mid-Study Updates Delay Trials At Least a Month, CSDD Report Finds

  • Real-TimeData-360x240.png

    Real-Time Data Helped Sponsors Respond to Sites’ Needs During the Pandemic

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing